Cargando…

Pasireotide Versus Octreotide in Preventing Complications After Simultaneous Pancreas-Kidney Transplantation

In elective pancreatic surgery, somatostatin-analogues pasireotide and octreotide are variably used to reduce postoperative complications, but knowledge on their role in pancreas transplantation is limited. This study compared pasireotide and octreotide for their association with complications after...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahopelto, Kaisa, Bonsdorff, Akseli, Grasberger, Juulia, Lempinen, Marko, Nordin, Arno, Helanterä, Ilkka, Sallinen, Ville
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300274/
https://www.ncbi.nlm.nih.gov/pubmed/37388858
http://dx.doi.org/10.3389/ti.2023.11255
_version_ 1785064551552647168
author Ahopelto, Kaisa
Bonsdorff, Akseli
Grasberger, Juulia
Lempinen, Marko
Nordin, Arno
Helanterä, Ilkka
Sallinen, Ville
author_facet Ahopelto, Kaisa
Bonsdorff, Akseli
Grasberger, Juulia
Lempinen, Marko
Nordin, Arno
Helanterä, Ilkka
Sallinen, Ville
author_sort Ahopelto, Kaisa
collection PubMed
description In elective pancreatic surgery, somatostatin-analogues pasireotide and octreotide are variably used to reduce postoperative complications, but knowledge on their role in pancreas transplantation is limited. This study compared pasireotide and octreotide for their association with complications after simultaneous pancreas-kidney transplantation (SPK). This retrospective study included consecutive patients undergoing SPK’s from July 2013 to July 2022. Between July 2013 and April 2020, octreotide was administered 0.1 mg s.c. once daily and between May 2020 and July 2022 pasireotide was administered 0.9 mg twice daily, both until third postoperative day. Complications within 90 days postoperatively were collected, and reoperation rate and Comprehensive Complication index (CCI) ≥ 33.7 (morbidity equal to one reoperation) were used as primary outcomes. Of the 213 patients undergoing SPK, 150 patients received octreotide and 63 pasireotide. Baseline characteristics were comparable. Reoperation rate was 25.3% (n = 38) and 17.5% (n = 11) (p = 0.213) and rate of CCI ≥ 33.7 was 40.7% (n = 61) and 30.2% (n = 19) (p = 0.148) in octreotide and pasireotide groups, respectively. When adjusted with donor BMI, pancreas donor risk index, and donor sex, receiving pasireotide translated into OR 0.49 (95% CI: 0.25–0.96 p = 0.037) for CCI ≥ 33.7. Pasireotide was independently associated with lower postoperative morbidity within 90 days of SPK compared to octreotide.
format Online
Article
Text
id pubmed-10300274
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103002742023-06-29 Pasireotide Versus Octreotide in Preventing Complications After Simultaneous Pancreas-Kidney Transplantation Ahopelto, Kaisa Bonsdorff, Akseli Grasberger, Juulia Lempinen, Marko Nordin, Arno Helanterä, Ilkka Sallinen, Ville Transpl Int Health Archive In elective pancreatic surgery, somatostatin-analogues pasireotide and octreotide are variably used to reduce postoperative complications, but knowledge on their role in pancreas transplantation is limited. This study compared pasireotide and octreotide for their association with complications after simultaneous pancreas-kidney transplantation (SPK). This retrospective study included consecutive patients undergoing SPK’s from July 2013 to July 2022. Between July 2013 and April 2020, octreotide was administered 0.1 mg s.c. once daily and between May 2020 and July 2022 pasireotide was administered 0.9 mg twice daily, both until third postoperative day. Complications within 90 days postoperatively were collected, and reoperation rate and Comprehensive Complication index (CCI) ≥ 33.7 (morbidity equal to one reoperation) were used as primary outcomes. Of the 213 patients undergoing SPK, 150 patients received octreotide and 63 pasireotide. Baseline characteristics were comparable. Reoperation rate was 25.3% (n = 38) and 17.5% (n = 11) (p = 0.213) and rate of CCI ≥ 33.7 was 40.7% (n = 61) and 30.2% (n = 19) (p = 0.148) in octreotide and pasireotide groups, respectively. When adjusted with donor BMI, pancreas donor risk index, and donor sex, receiving pasireotide translated into OR 0.49 (95% CI: 0.25–0.96 p = 0.037) for CCI ≥ 33.7. Pasireotide was independently associated with lower postoperative morbidity within 90 days of SPK compared to octreotide. Frontiers Media S.A. 2023-06-14 /pmc/articles/PMC10300274/ /pubmed/37388858 http://dx.doi.org/10.3389/ti.2023.11255 Text en Copyright © 2023 Ahopelto, Bonsdorff, Grasberger, Lempinen, Nordin, Helanterä and Sallinen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Health Archive
Ahopelto, Kaisa
Bonsdorff, Akseli
Grasberger, Juulia
Lempinen, Marko
Nordin, Arno
Helanterä, Ilkka
Sallinen, Ville
Pasireotide Versus Octreotide in Preventing Complications After Simultaneous Pancreas-Kidney Transplantation
title Pasireotide Versus Octreotide in Preventing Complications After Simultaneous Pancreas-Kidney Transplantation
title_full Pasireotide Versus Octreotide in Preventing Complications After Simultaneous Pancreas-Kidney Transplantation
title_fullStr Pasireotide Versus Octreotide in Preventing Complications After Simultaneous Pancreas-Kidney Transplantation
title_full_unstemmed Pasireotide Versus Octreotide in Preventing Complications After Simultaneous Pancreas-Kidney Transplantation
title_short Pasireotide Versus Octreotide in Preventing Complications After Simultaneous Pancreas-Kidney Transplantation
title_sort pasireotide versus octreotide in preventing complications after simultaneous pancreas-kidney transplantation
topic Health Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300274/
https://www.ncbi.nlm.nih.gov/pubmed/37388858
http://dx.doi.org/10.3389/ti.2023.11255
work_keys_str_mv AT ahopeltokaisa pasireotideversusoctreotideinpreventingcomplicationsaftersimultaneouspancreaskidneytransplantation
AT bonsdorffakseli pasireotideversusoctreotideinpreventingcomplicationsaftersimultaneouspancreaskidneytransplantation
AT grasbergerjuulia pasireotideversusoctreotideinpreventingcomplicationsaftersimultaneouspancreaskidneytransplantation
AT lempinenmarko pasireotideversusoctreotideinpreventingcomplicationsaftersimultaneouspancreaskidneytransplantation
AT nordinarno pasireotideversusoctreotideinpreventingcomplicationsaftersimultaneouspancreaskidneytransplantation
AT helanterailkka pasireotideversusoctreotideinpreventingcomplicationsaftersimultaneouspancreaskidneytransplantation
AT sallinenville pasireotideversusoctreotideinpreventingcomplicationsaftersimultaneouspancreaskidneytransplantation